Defective cell cycle checkpoints as targets for anti-cancer therapies.
about
Cell Cycle Regulatory Functions of the KSHV Oncoprotein LANADNA damage response and prostate cancer: defects, regulation and therapeutic implicationsKaposi sarcoma herpes virus latency associated nuclear antigen protein release the G2/M cell cycle blocks by modulating ATM/ATR mediated checkpoint pathwayEssential oils and their constituents as anticancer agents: a mechanistic view.Genistein abrogates G2 arrest induced by curcumin in p53 deficient T47D cellsKnockdown of regulator of cullins-1 (ROC1) expression induces bladder cancer cell cycle arrest at the G2 phase and senescence.Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cellsTargeting Membrane Lipid a Potential Cancer Cure?DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma.Cell death and deubiquitinases: perspectives in cancer.Physalin A induces G2/M phase cell cycle arrest in human non-small cell lung cancer cells: involvement of the p38 MAPK/ROS pathway.How do tumor cells respond to HDAC inhibition?Cell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities.Identifying CDKN3 Gene Expression as a Prognostic Biomarker in Lung Adenocarcinoma via Meta-analysis.Chemo-sensitisation of HeLa cells to etoposide by a benzoxazine in the absence of DNA-PK inhibition.Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.Mechanisms of cancer cell killing by sea cucumber-derived compounds.Dietary compound proanthocyanidins from Chinese bayberry (Myrica rubra Sieb. et Zucc.) leaves attenuate chemotherapy-resistant ovarian cancer stem cell traits via targeting the Wnt/β-catenin signaling pathway and inducing G1 cell cycle arrest.Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.Deoxyribonucleic Acid Damage and Repair: Capitalizing on Our Understanding of the Mechanisms of Maintaining Genomic Integrity for Therapeutic Purposes.Dietary Compound Proanthocyanidins from Chinese bayberry (Myrica rubra Sieb. et Zucc.) leaves inhibit angiogenesis and regulate cell cycle of cisplatin-resistant ovarian cancer cells via targeting Akt pathway.Etoposide radiosensitizes p53-defective cholangiocarcinoma cell lines independent of their G2 checkpoint efficacies.
P2860
Q26749612-8544873F-808D-4EDD-8257-17EDBE0ED9EDQ26829155-CD16E921-2095-432D-A4B2-2971A242C3FBQ28540116-7CCED3B9-C030-4454-B344-66876AF31DB0Q33805315-54E2B255-FA70-4DD6-AA05-6E789FBB6FDFQ34564108-DFCFDA8A-9221-4323-AA3E-05B3F2ACE251Q34717627-72DA18A4-8BF2-43BD-82F3-8EC3C92725BBQ35154556-2901A7C9-12DD-439B-B29D-365548DC8F16Q37597900-EBBBBCE9-F1A6-4057-952D-307C6E7ACB30Q38120311-A65DE744-C06A-49B3-9D73-A8497BA20EB6Q38239700-B75C22E1-53E5-4CAC-A3E1-6EB613FA61BEQ38784376-F8CDC798-9CAC-4408-B3DF-B913D93CAB4FQ38817005-03B3C5B6-CE72-4A04-8220-FF291A885735Q39191984-5712FE78-2E8C-4F5F-9646-D9C148373EF2Q41090797-46A1C20F-0E7C-4B9C-A0F2-B9E0418E0492Q41832240-8FD8C235-AE94-418F-8609-CEE4D296C385Q47101582-6B10B1EE-E7CF-4788-948D-ED8E64DD2605Q47134021-7F30C434-77C7-4814-B2F0-2AC33A40935AQ47277352-36019616-1FA5-47E3-80A2-C42FD1068639Q48534871-A3636193-8E31-4C85-A70E-EEB5EDA6D0E3Q52720061-2F13E863-1EC3-48B6-8686-6B8BFBBDE34AQ52724257-688F6F3E-2C40-4884-9B1D-3A718D88E967Q52726503-E99543AF-629E-4AF2-A464-42762FE0F31F
P2860
Defective cell cycle checkpoints as targets for anti-cancer therapies.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Defective cell cycle checkpoints as targets for anti-cancer therapies.
@en
type
label
Defective cell cycle checkpoints as targets for anti-cancer therapies.
@en
prefLabel
Defective cell cycle checkpoints as targets for anti-cancer therapies.
@en
P2093
P2860
P356
P1476
Defective cell cycle checkpoints as targets for anti-cancer therapies.
@en
P2093
Brian Gabrielli
Kelly Brooks
Sandra Pavey
P2860
P356
10.3389/FPHAR.2012.00009
P577
2012-02-02T00:00:00Z